Comparative Pharmacology
Head-to-head clinical analysis: VANCOCIN HYDROCHLORIDE versus VANCOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VANCOCIN HYDROCHLORIDE versus VANCOR.
VANCOCIN HYDROCHLORIDE vs VANCOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vancomycin inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of cell wall precursor units, thereby preventing polymerization and cross-linking of peptidoglycan.
Inhibits cell wall synthesis by binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors, blocking transglycosylation and transpeptidation.
15-20 mg/kg IV every 8-12 hours; maximum single dose 2 g. Target trough 10-20 mcg/mL.
Vancomycin 15-20 mg/kg IV every 8-12 hours, with target trough 10-20 mcg/mL; for serious infections, consider loading dose 25-30 mg/kg IV.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults with normal renal function; prolonged to 7-9 days in anuric patients, necessitating therapeutic drug monitoring.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; can extend to 7-9 days in anuric patients, necessitating therapeutic drug monitoring.
Primarily renal (glomerular filtration): 80-90% of dose excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination (<5%).
Renal excretion of unchanged drug accounts for 80-90% of clearance via glomerular filtration; minor biliary excretion (<5%) and fecal elimination (<5%).
Category C
Category C
Glycopeptide Antibiotic
Glycopeptide Antibiotic